GSK’s older adult respiratory syncytial virus (RSV) vaccine candidate shows 94.1% reduction in severe RSV disease and overall vaccine efficacy of 82.6% in ...
Data showed overall vaccine efficacy against RSV-lower respiratory tract disease in adults aged 60 years and above| www.gsk.com
